Do you want to read an article? Please log in or register.
ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors
Breast Cancer
ESMO 2025
Related content
CHICAGO 2025
Breast Cancer
LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Thorac Oncol
Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H
doi: 10.1016/j.jtho.2025.03.033
SABCS 2024
Breast Cancer
PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer
Lung, Respiratory and Thoracic Cancer
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Lung Cancer
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K
doi: 10.1016/j.lungcan.2025.108104
Lung, Respiratory and Thoracic Cancer
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Clin Cancer Res
Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X
doi: 10.1158/1078-0432.CCR-25-1735
ELCC 2025
Lung, Respiratory and Thoracic Cancer
MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC
Lung, Respiratory and Thoracic Cancer
Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis
Lung Cancer
Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L
doi: 10.1016/j.lungcan.2025.108450
Lung, Respiratory and Thoracic Cancer
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
J Thorac Oncol
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS
doi: 10.1016/j.jtho.2025.05.019
Lung, Respiratory and Thoracic Cancer
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01
Eur J Cancer
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M
doi: 10.1016/j.ejca.2024.115117